儿童清咽解热口服液联合开喉剑喷雾剂治疗小儿急性咽炎疗效观察及对免疫功能的影响  

Observation on Therapeutic Effect of Er'tong Qingyan Jiere Oral Liquid Combined with Kaihoujian Spray for Acute Pharyngitis in Children and Its Influence on Immune Function

作　　者：杨静[1] 朱萍[1] 王书举[1] YANG Jing;ZHU Ping;WANG Shuju(Department of Pediatric Respiratory,Nanyang Central Hospital,Nanyang Henan 473000,China)

机构地区：[1]南阳市中心医院儿童呼吸科,河南南阳473000

出　　处：《新中医》2025年第4期46-50,共5页New Chinese Medicine

摘　　要：目的:观察儿童清咽解热口服液联合开喉剑喷雾剂治疗小儿急性咽炎临床疗效及对免疫功能的影响。方法:选取2022年3月—2023年3月南阳市中心医院收治的小儿急性咽炎86例,按照随机数字表法分为治疗组和对照组各43例。治疗组采用儿童清咽解热口服液联合开喉剑喷雾剂治疗,对照组采用头孢克肟颗粒治疗。治疗7天后,比较2组临床疗效、中医证候评分、免疫功能(T淋巴细胞CD3^(+)、CD4^(+)、CD8^(+)及CD4^(+)/CD8^(+)水平)及不良反应发生情况。结果:治疗组总有效率为95.35%(41/43),对照组为76.74%(33/43),组间比较,差异有统计学意义(P<0.05)。治疗后,治疗组咽部红肿、发热、咽痛、咳痰消退时间均短于对照组(P<0.05)。治疗后,2组中医证候中主、次症评分均较治疗前降低(P<0.05),且治疗组主、次症评分均低于对照组(P<0.05)。治疗后,2组血清CD3^(+)、CD4^(+)及CD4^(+)/CD8^(+)水平均较治疗前升高(P<0.05),CD8^(+)水平均较治疗前降低(P<0.05);且治疗组CD3^(+)、CD4^(+)及CD4^(+)/CD8^(+)水平高于对照组(P<0.05),CD8^(+)水平低于对照组(P<0.05)。治疗期间,治疗组不良反应发生率为11.63%(5/43),对照组为6.98%(3/43),2组比较,差异无统计学意义(P>0.05)。结论:儿童清咽解热口服液联合开喉剑喷雾剂治疗小儿急性咽炎疗效肯定,可有效缓解患儿临床症状,加速症状消退,有效改善患儿免疫功能。Objective:To observe the effect of Er'tong Qingyan Jiere Oral Liquid combined with Kaihoujian Spray on children with acute pharyngitis and its influence on immune function.Methods:A total of 86 children with acute pharyngitis treated in Nanyang Central Hospital from March 2022 to March 2023 were selected and divided into the treatment group and the control group according to random number table method,with 43 cases in each group.The treatment group was treated with Er'tong Qingyan Jiere Oral Liquid combined with Kaihoujian Spray,and the control group was treated with Cefixime Granules.After seven days of treatment,the clinical effects,traditional Chinese medicine syndrome scores,immune function(T lymphocyte CD3^(+),CD4^(+),CD8^(+)and CD4^(+)/CD8^(+)levels)and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate was 95.35%(41/43)in the treatment group and 76.74%(33/43)in the control group,the difference being significant(P<0.05).After treatment,the regression time of pharyngeal redness,fever,pharyngeal pain and expectoration in the treatment group was storter than that in the control group(P<0.05).After treatment,the scores of primary and secondary syndromes in the two groups were decreased when compared with those before treatment(P<0.05),and the scores of primary and secondary syndromes in the treatment group were lower than those in the control group(P<0.05).After treatment,the levels of serum CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the two groups were increased when compared with those before treatment(P<0.05),and the CD8^(+)levels were decreased when compared with those before treatment(P<0.05).The levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the treatment group were higher than those in the control group(P<0.05),and the CD8^(+)level was lower than that in the control group(P<0.05).The incidence of adverse reactions was 11.63%(5/43)in the treatment group and 6.98%(3/43)in the control group,there being no significant difference between the two groups(P>0.05).C

关 键 词：小儿急性咽炎 儿童清咽解热口服液 开喉剑喷雾剂 免疫功能 

分 类 号：R725.6[医药卫生—儿科]